{"id":1020241,"date":"2026-11-12T08:39:33","date_gmt":"2026-11-12T13:39:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pelthos-therapeutics-announces-third-quarter-2026-financial-results-and-provides-business-update\/"},"modified":"2026-11-12T08:39:33","modified_gmt":"2026-11-12T13:39:33","slug":"pelthos-therapeutics-announces-third-quarter-2026-financial-results-and-provides-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pelthos-therapeutics-announces-third-quarter-2026-financial-results-and-provides-business-update\/","title":{"rendered":"Pelthos Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Update"},"content":{"rendered":"
\n

\n Zelsuvmi<\/em>
\n \u00ae<\/sup>
\n net product revenue grew <\/em>
\n 114%<\/em>
\n to <\/em>
\n $15.2 million<\/em>
\n during the <\/em>
\n third<\/em>
\n quarter of <\/em>
\n 2026<\/em>
\n from <\/em>
\n $7.1 million<\/em>
\n in the <\/em>
\n third<\/em>
\n quarter of 2025<\/em>\n <\/p>\n

\n 12,384<\/em>
\n Zelsuvmi units were dispensed by <\/em>
\n 4,942<\/em>
\n unique prescribers during the <\/em>
\n third<\/em>
\n quarter of <\/em>
\n 2026<\/em>
\n , representing a <\/em>
\n 4%<\/em>
\n quarter-over-quarter increase in units dispensed<\/em>\n <\/p>\n

\n Increased formulary coverage for Zelsuvmi<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n to 127 million commercially covered lives<\/em>\n <\/p>\n

\n Recently announced transaction with Castle Creek, creating transformative biotechnology company focused on serious diseases that affect the skin<\/em>\n <\/p>\n

\n Management will host a conference call today, <\/em>
\n November\u00a012, 2026<\/em>
\n , at 8:30 a.m. ET<\/em>\n <\/p>\n

\n
\n
\n <\/strong>DURHAM, N.C., Nov. 12, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (\u201cPelthos,\u201d \u201cwe\u201d or the \u201cCompany\u201d), today announced its financial results for the third quarter ended September\u00a030, 2026, and provided a business update.<\/p>\n

\u201cZelsuvmi delivered another solid quarter, generating net product revenue of $15.2 million,\u201d said Scott Plesha, CEO of Pelthos. \u201cThousands of patients have already benefited from Zelsuvmi and we remain focused on driving Zelsuvmi growth and building on our success with the planned launches of Xepi\u00ae targeted in the first quarter of 2027 and Xeglyze\u00ae targeted in the third quarter of 2027.\u201d<\/p>\n

\u201cIn October, after the close of the third quarter, we took an important step in our pursuit of long-term value by announcing our agreement to combine with Castle Creek, a transaction that we believe will create a stronger, more diversified biotechnology company,\u201d Mr. Plesha continued. \u201cThis transformative merger brings together two complementary platforms across different therapeutic modalities and has significant upside potential through Castle Creek\u2019s fibroblast-based cell and gene therapy technology, and its lead candidate, D-Fi, which has the potential to become a blockbuster franchise in dystrophic epidermolysis bullosa, or DEB. We look forward to completing the transaction and delivering significant value to our shareholders.\u201d<\/p>\n

\n Third<\/strong>
\n Quarter and Recent Business Highlights<\/strong>\n <\/p>\n

\n
\n Zelsuvmi<\/em>
\n <\/strong>
\n
\n
\n \u00ae<\/em>
\n <\/strong>
\n <\/sup>
\n
\n Commercial Highlights<\/em>
\n <\/strong>\n <\/p>\n